Kate Andrews Kate Andrews

Could Ozempic actually boost Britain’s labour market?

Credit: Getty images

Is Ozempic the miracle fix for Britain’s labour market woes? This morning Health Secretary Wes Streeting has announced a £280 million investment into the UK from US pharmaceutical giant Lilly, which will include the first ‘real-world trial’ to give weight-loss jabs to people out of work. The news coincides with the publication of the latest labour market overview by the Office for National Statistics, showing the number of people out of work due to long-term sickness is still at a near-record high: 2.75 million in the three months to August.

As Streeting highlights in the Daily Telegraph today, obesity is creating both a strain on the health service and on the economy. As costs rise for the NHS to treat obesity-related illness, the additional revenue that might help pay for such treatments is being lost due to so many working-age people being out of a job.

Comments

Join the debate for just $5 for 3 months

Be part of the conversation with other Spectator readers by getting your first three months for $5.

Already a subscriber? Log in